Multi-institutional experience with COVID-19 convalescent plasma in children.

ABSTRACT:

Background and objectives

Convalescent COVID-19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high-titer CCP early in the disease course of patients who are expected to be antibody-negative; however, pediatric experience is limited. We created a multi-institutional registry to characterize pediatric patients (<18 years) who received CCP and to assess the safety of this intervention.

Methods

A REDCap survey was distributed. The registry collected de-identified data including demographic information (age, gender, and underlying conditions), COVID-19 disease features and concurrent treatments, CCP transfusion and safety events, and therapy response.

Results

Ninety-five children recei

SUBMITTER: Jacquot C 

PROVIDER: S-EPMC10175190 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature